TY - JOUR
T1 - Single-cell profiling of cutaneous T-cell lymphoma reveals underlying heterogeneity associated with disease progression
AU - Borcherding, Nicholas
AU - Voigt, Andrew P.
AU - Liu, Vincent
AU - Link, Brian K.
AU - Zhang, Weizhou
AU - Jabbari, Ali
N1 - Publisher Copyright:
© 2019 American Association for Cancer Research.
PY - 2019
Y1 - 2019
N2 - Purpose: Cutaneous T-cell lymphomas (CTCL), encompassing a spectrum of T-cell lymphoproliferative disorders involving the skin, have collectively increased in incidence over the last 40 years. Sezary syndrome is an aggressive form of CTCL characterized by significant presence of malignant cells in both the blood and skin. The guarded prognosis for Sezary syndrome reflects a lack of reliably effective therapy, due, in part, to an incomplete understanding of disease pathogenesis. Experimental Design: Using single-cell sequencing of RNA and the machine-learning reverse graph embedding approach in the Monocle package, we defined a model featuring distinct transcriptomic states within Sezary syndrome. Gene expression used to differentiate the unique transcriptional states were further used to develop a boosted tree classification for early versus late CTCL disease. Results: Our analysis showed the involvement of FOXP3þ malignant T cells during clonal evolution, transitioning from FOXP3þ T cells to GATA3þ or IKZF2þ (HELIOS) tumor cells. Transcriptomic diversities in a clonal tumor can be used to predict disease stage, and we were able to characterize a gene signature that predicts disease stage with close to 80% accuracy. FOXP3 was found to be the most important factor to predict early disease in CTCL, along with another 19 genes used to predict CTCL stage. Conclusions: This work offers insight into the heterogeneity of Sezary syndrome, providing better understanding of the transcriptomic diversities within a clonal tumor. This transcriptional heterogeneity can predict tumor stage and thereby offer guidance for therapy.
AB - Purpose: Cutaneous T-cell lymphomas (CTCL), encompassing a spectrum of T-cell lymphoproliferative disorders involving the skin, have collectively increased in incidence over the last 40 years. Sezary syndrome is an aggressive form of CTCL characterized by significant presence of malignant cells in both the blood and skin. The guarded prognosis for Sezary syndrome reflects a lack of reliably effective therapy, due, in part, to an incomplete understanding of disease pathogenesis. Experimental Design: Using single-cell sequencing of RNA and the machine-learning reverse graph embedding approach in the Monocle package, we defined a model featuring distinct transcriptomic states within Sezary syndrome. Gene expression used to differentiate the unique transcriptional states were further used to develop a boosted tree classification for early versus late CTCL disease. Results: Our analysis showed the involvement of FOXP3þ malignant T cells during clonal evolution, transitioning from FOXP3þ T cells to GATA3þ or IKZF2þ (HELIOS) tumor cells. Transcriptomic diversities in a clonal tumor can be used to predict disease stage, and we were able to characterize a gene signature that predicts disease stage with close to 80% accuracy. FOXP3 was found to be the most important factor to predict early disease in CTCL, along with another 19 genes used to predict CTCL stage. Conclusions: This work offers insight into the heterogeneity of Sezary syndrome, providing better understanding of the transcriptomic diversities within a clonal tumor. This transcriptional heterogeneity can predict tumor stage and thereby offer guidance for therapy.
UR - http://www.scopus.com/inward/record.url?scp=85065773202&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-18-3309
DO - 10.1158/1078-0432.CCR-18-3309
M3 - Article
C2 - 30718356
AN - SCOPUS:85065773202
SN - 1078-0432
VL - 25
SP - 2996
EP - 3005
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 10
ER -